In Vivo and in Silico Based Evaluation of Antidiabetic Potential of an Isolated Flavonoid from Allium hookeri in Type 2 Diabetic Rat Model

Abstract

Allium hookeri (F: Liliaceae), an indigenous plant of Manipur, India, is traditionally used to treat various diseases and disorders like diabetes, hypertension, and stomach ache. In our previous study, the methanol extract of the plant showed significant antidiabetic potential in rats. In the present study, we evaluated the antidiabetic potential of a flavonoid compound named MEA isolated from the methanolic leaf extract of A. Hookeri in rats. Additionally, we assessed the compound's mode of action through the molecular docking study. The MEA reduced the blood glucose level from 317±12.8 to 99.4±6.67 mg/dl after 21 days of treatment. Besides, MEA also restored the body weights and other biochemical parameters including lipid profile significantly compared to the diabetic group (p<0.001). The histoarchitecture of the pancreatic tissues of the MEA treated group was also improved compared to the diabetic group. In the docking study, the compound showed good binding affinity in the active binding site of the two structures of pancreatic beta‐cell SUR1 (Sulfonylurea Receptor 1) subunit with CDocker energy −31.556 kcal/mol and −39.703 kcal/mol, respectively. The compound MEA was found to be drug‐like with non‐carcinogenic, non‐mutagenic and non‐irritant properties. These findings indicate the antidiabetic potential of MEA, which might act by modulating the pancreatic beta‐cell SUR1 subunit present in the K _ATP channel. Hence, the MEA would be a promising lead molecule to develop new antidiabetic drug candidates of the future.